TrialThe Journal of international medical research2024

Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.

Qi Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.